0001209191-23-034886.txt : 20230606
0001209191-23-034886.hdr.sgml : 20230606
20230606193512
ACCESSION NUMBER: 0001209191-23-034886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230602
FILED AS OF DATE: 20230606
DATE AS OF CHANGE: 20230606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOEBIUS HANS
CENTRAL INDEX KEY: 0001822494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39503
FILM NUMBER: 23997410
MAIL ADDRESS:
STREET 1: 4000 MASON ROAD, SUITE 300
STREET 2: BOX 352141
CITY: SEATTLE
STATE: WA
ZIP: 98195-2141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athira Pharma, Inc.
CENTRAL INDEX KEY: 0001620463
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 453368487
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104
CITY: BOTHELL
STATE: WA
ZIP: 98011
BUSINESS PHONE: (425) 620-8501
MAIL ADDRESS:
STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104
CITY: BOTHELL
STATE: WA
ZIP: 98011
FORMER COMPANY:
FORMER CONFORMED NAME: M3 Biotechnology, Inc.
DATE OF NAME CHANGE: 20140924
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-02
0
0001620463
Athira Pharma, Inc.
ATHA
0001822494
MOEBIUS HANS
C/O ATHIRA PHARMA, INC.
18706 NORTH CREEK PARKWAY, SUITE 104
BOTHELL
WA
98011
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-05-18
5
A
0
E
7764
2.41
A
73600
D
Common Stock
2023-06-02
4
M
0
7882
1.35
A
81482
D
Stock Option (Right to Buy)
1.35
2023-06-02
4
M
0
7882
0.00
D
2029-08-14
Common Stock
7882
0
D
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c).
The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023.
One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.
/s/ Mark Worthington, Attorney-in-Fact for Hans Moebius
2023-06-06